Group 1 - The core point of the article is that Bai'ao Saitou (688796.SH) has released its prospectus for an initial public offering (IPO) on the Sci-Tech Innovation Board, planning to issue 47.5 million shares, which will account for 10.63% of the total share capital post-issue [1] - The company was established in 2009 and operates as a preclinical CRO and biotechnology firm, providing innovative animal models and preclinical drug development services based on its proprietary gene editing technology [1][2] - The company has completed approximately 5,300 customized gene editing projects and developed over 4,300 types of gene-edited animals and cell line models, expanding its business into innovative animal sales, preclinical pharmacology evaluation services, and antibody drug collaboration [2] Group 2 - The company's main business revenue for the reporting periods were 533 million yuan, 716 million yuan, 980 million yuan, and 621 million yuan, with a compound annual growth rate of 35.56% from 2022 to 2024 [2] - The funds raised from the IPO, after deducting issuance costs, will be invested in projects including early drug development service platform construction, antibody drug research and evaluation, preclinical research projects, and supplementing working capital, totaling 1.185 billion yuan [3]
临床前CRO以及生物技术企业百奥赛图(688796.SH)拟于科创板IPO上市